PT-141 (Bremelanotide) Peptide – User Manual & Research Protocol Guide

PT-141 (Bremelanotide) is a melanocortin receptor agonist studied for its role in neuroendocrine signaling and sexual behavior pathways. In research environments, it is investigated for central nervous system receptor activity, arousal physiology, and hormone-independent signaling mechanisms.

Research Applications

Melanocortin receptor signaling studies
Neuroendocrine response research
Arousal physiology and CNS pathway models
Hormone-independent signaling investigations
Behavioral response research

Disclaimer: PT-141 is for research and experimental use only and is not FDA-approved for therapeutic use.

Lyophilized Powder

Freeze-dried PT‑141 intended for reconstitution prior to use in research settings.

Reconstituted Solution

Prepared liquid form used as an injectable research preparation after proper reconstitution.

PT-141 is studied for its ability to:

• Activate melanocortin receptors in experimental models
• Influence central nervous system signaling pathways
• Modulate neuroendocrine response mechanisms
• Support investigation of arousal-related physiology
• Operate independently of vascular nitric oxide pathways

Observed effects are derived from preclinical and investigational research settings.

Subcutaneous (SC) – Standard Research Model

Typical research protocols use 0.5–2 mg per administration, with frequency as directed by the study protocol, often in receptor signaling studies.

Short-Course Research

Some studies use 0.5–1 mg intermittently, with scheduling dependent on protocol design.

Protocol-Based Study

Dosing and frequency are protocol-dependent, determined by the specific research design and objectives.

Important

There is no approved human dosage for research use. The ranges above reflect commonly cited research patterns only.

Initiation

A single administration phase used for initial response observation.

Active Study Phase

A variable-duration phase focused on evaluating central nervous system (CNS) pathways.

Rest Period

A protocol-dependent interval allowing recovery between research cycles.

Note

Cycle duration may vary depending on the research design and study endpoints.

Supplies

Sterile bacteriostatic water
Sterile syringe
Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.
   Example: 10 mg vial + 2 mL → 5 mg/mL
3. Swirl gently to dissolve (do not shake).
4. Refrigerate at 2–8°C after reconstitution.
5. Use within 2–4 weeks or per protocol.

Maintain sterile technique
Rotate administration sites in injectable models
Document preparation concentration and date
Follow institutional research standards

Lyophilized Powder

Store in a cool, dry environment to maintain stability, with a shelf life of up to 12 months.

Reconstituted Solution

Keep refrigerated at 2–8°C and use within 2–4 weeks after preparation.

Protection Guidelines

Protect from light, heat, and contamination to preserve quality.

Safety Note

Discard the solution if it becomes cloudy or discolored, as this may indicate contamination or degradation.

Research use only
Not for therapeutic application
Human safety outside controlled research is not established
Potential research observations: flushing, nausea, injection-site irritation
Maintain sterile handling technique
Keep out of reach of unauthorized personnel

Peptide: PT-141 (Bremelanotide)
Category: Neuroendocrine & Sexual Health Research
Delivery: Injectable research model
Typical Investigational Range: 0.5–2 mg per administration
Cycle: Protocol-dependent
Storage: Refrigerated after reconstitution